Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02613598
Title Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Michgan Comprehensive Cancer Center Ann Arbor Michigan 48187 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field